A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.

This disclosure provides compositions comprising a collagen polypeptide (e.g., a human type 21 collagen polypeptide or a truncate thereof) or an elastin polypeptide (e.g., a human elastin polypeptide or a truncate thereof), and one or more active ingredient. This disclosure also provides compositions comprising an elastin polypeptide (e.g., a human elastin polypeptide or a truncate thereof) in combination with a collagen polypeptide or truncate thereof. This disclosure further provides formulations comprising said composition, such as personal care products. This disclosure further provides methods of using the compositions and formulations provided herein (e.g., for application to the skin and/or hair a subject).

This disclosure provides compositions comprising a collagen polypeptide (e.g., a human type 21 collagen polypeptide or a truncate thereof) or an elastin polypeptide (e.g., a human elastin polypeptide or a truncate thereof), and one or more active ingredient. This disclosure also provides compositions comprising an elastin polypeptide (e.g., a human elastin polypeptide or a truncate thereof) in combination with a collagen polypeptide or truncate thereof. This disclosure further provides formulations comprising said composition, such as personal care products. This disclosure further provides methods of using the compositions and formulations provided herein (e.g., for application to the skin and/or hair a subject).

Encapsulated peroxide particles inhibit skin inflammation. A method of encapsulating a solid peroxide comprises dispersing solid peroxide particles (e.g., benzoyl peroxide) in an aqueous dispersion of fatty acid salt to form a peroxide/fatty acid salt dispersion, wherein the peroxide particles have a mean particle size (D50) of 10 μm or less; and subsequently encapsulating the solid peroxide particles by reacting the one or more monovalent fatty acid salts with one or more multivalent salts of calcium, magnesium, aluminum, silver, and/or zinc, thereby forming encapsulated peroxide particles.

Encapsulated peroxide particles inhibit skin inflammation. A method of encapsulating a solid peroxide comprises dispersing solid peroxide particles (e.g., benzoyl peroxide) in an aqueous dispersion of fatty acid salt to form a peroxide/fatty acid salt dispersion, wherein the peroxide particles have a mean particle size (D50) of 10 μm or less; and subsequently encapsulating the solid peroxide particles by reacting the one or more monovalent fatty acid salts with one or more multivalent salts of calcium, magnesium, aluminum, silver, and/or zinc, thereby forming encapsulated peroxide particles.

A consumer product including a personal care composition providing multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules.

A consumer product including a personal care composition providing multiple blooms of fragrance, the multiple blooms being provided for by different populations of microcapsules.

A chewable composition for teeth-whitening comprising a first region and a second region separated by a barrier layer; the first region comprising carbamide peroxide having water content of about 2% or less, a wetting agent (e.g., glycerin), an anhydrous chewing gum base having water content of about 1% or less, an anhydrous fruit acid, and one or more gum additives; and the second region comprising a chewable composition comprising a gum base, a source of bicarbonate ion, and one or more gum additives. A kit comprising separate chewable compositions corresponding to the first and second regions, and methods for whitening teeth using the chewable composition are also provided.

A chewable composition for teeth-whitening comprising a first region and a second region separated by a barrier layer; the first region comprising carbamide peroxide having water content of about 2% or less, a wetting agent (e.g., glycerin), an anhydrous chewing gum base having water content of about 1% or less, an anhydrous fruit acid, and one or more gum additives; and the second region comprising a chewable composition comprising a gum base, a source of bicarbonate ion, and one or more gum additives. A kit comprising separate chewable compositions corresponding to the first and second regions, and methods for whitening teeth using the chewable composition are also provided.

A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.